Deciphera Pharmaceuticals to Present Clinical Data on Tumor Targeted Advanced Kinase Inhibitors at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing tumor-targeted and immuno-targeted advanced kinase inhibitors, announced today that two abstracts featuring the Company’s clinical-stage tumor-targeted therapies have been selected for a late-breaking oral presentation and a poster discussion at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 to December 2, 2016 in Munich, Germay. DCC-2618 is a pan-KIT and PDGFRα kinase inhibitor in clinical development for the treatment of genetically-defined cancers, including gastrointestinal stromal tumors (GIST) and other KIT-driven cancers such as systemic mastocytosis. Altiratinib is a spectrum selective inhibitor of MET, TRK, TIE2 & VEGFR2 kinases in clinical development for the treatment of solid tumors. DCC-2618 and altiratinib are both currently in Phase 1 first-in-human studies. “Genetically-defined cancers with specific kinase mutations, such as gastrointestinal stromal tumors and systemic mastocytosis, are ideal targets for our advanced kinase inhibitors and we look forward to sharing clinical data on DCC-2618 and altiratinib at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,” stated Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals. Late-breaking Oral Presentation: Title: DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study Author: Janku, F., MD Anderson Cancer Center Abstract: 7LBA Session: Plenary Session 6: Proffered Paper Session Date/Time: Thursday, December 1, 2016, 4:10 p.m. (CET) Poster Presentation: Title: The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants Author: Drilon, A. Abstract/Board: 422/P101 Session: Poster Session: Molecular targeted agents II Date/Time: Thursday, December 1, 2016, 10:15 a.m. – 5:00 p.m. (CET) About Deciphera Pharmaceuticals Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing innovative kinase inhibitor therapies that address key drug resistance mechanisms. Deciphera’s unique approach leverages its deep understanding of kinase biology to develop a robust pipeline of tumor-targeted and immuno-targeted drug candidates that can improve the rate and durability of response to treatment. Deciphera’s innovative switch control platform enables the creation of tumor-targeted agents designed to control therapeutic resistance causing mutations and immuno-targeted agents designed to control activation of immuno-kinases that suppress critical immune system regulators, such as macrophages. This two-pronged approach to kinase inhibition represents an advance over other methods of inhibiting kinases for the treatment of cancer. Contacts: Michael D. Taylor, Ph.D., Deciphera Pharmaceuticals, LLC [email protected] 781-209-6411 Media: Gina Nugent, The Yates Network [email protected] 617-460-3579 twitter linkedin contact us Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3009 Inlexisertib DCC-2812 Expanded Access Our Medicine About Management Join Us Open Positions Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement Compliance Hotline Consent Manager © 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo. Back to top

The release as fetched from its publisher. deciphera.com ↗